stockrow
Saturday 7 November 2026
Export AZTR’s income statement to Excel — free account
Azitra, Inc.
AZTR Healthcare Biotechnology
Azitra, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $7,500.00, down 98.9% from fiscal 2023.
- EPS
- +85.3%
- Free cash flow
- −19.6%
Quarter to June 2026, against a year earlier
0.75
0.02
+2.74%
Follow AZTR
Alert me
| Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | — | 3 | 3 | — |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | — |
P/S ratio |
13.46 | 13.46 | 10.70 | 2.79 | — |
Altman Z-Score |
— | — | (16.00) | (14.66) | — |
Altman Z″-Score (non-manufacturers) |
(16.73) | (24.96) | (38.17) | (28.50) | — |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | — |
Beneish M-Score |
— | (2.16) | (5.04) | 13.02 | — |
P/Operating CF |
(3.78) | (3.78) | (2.89) | (0.63) | — |
P/B ratio |
0.00 | 0.00 | 2.52 | 0.28 | — |
Price to Tangible BV |
0.00 | 0.00 | 2.72 | 0.30 | — |
EV/Sales |
28.00 | 28.00 | 8.12 | (5.04) | — |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.29 | — |
EV/Operating CF |
(1.06) | (1.06) | (0.76) | 0.29 | — |
EV/FCF |
(1.02) | (1.02) | (0.73) | 0.28 | — |
Quick Ratio |
6.93 | 1.69 | 1.26 | 3.38 | 2.07 |
Current Ratio |
7.02 | 1.86 | 1.58 | 3.80 | 2.83 |
Net Debt/EBITDA |
(2.92) | (0.34) | 0.27 | 0.45 | 0.20 |
Debt/Assets |
340.02% | 92.08% | 0.51% | 0.14% | 0.00% |
Debt/Equity |
(1.35) | (0.18) | 0.01 | 0.00 | 0.00 |
Asset Turnover |
0.00 | 0.03 | 0.11 | 0.00 | 0.00 |
Operating CF/Net income |
0.69 | 0.62 | 0.58 | 1.14 | 1.02 |
Capex/Depreciation |
0.00 | (0.81) | (0.41) | (0.43) | (0.40) |
Interest Coverage |
(243.31) | (37.53) | (44.43) | (900.42) | (1,442.99) |
| 0.00% | 43.37% | 75.80% | (208.27%) | (230.65%) | |
| 0.00% | (154.87%) | (205.80%) | (143.78%) | (176.93%) | |
ROIC |
0.00% | 0.00% | (407.29%) | (595.10%) | (395.49%) |
Return on Tangible Assets |
(142.34%) | (487.14%) | (769.50%) | (198.99%) | (438.23%) |
Average Days of Receivables |
1,108.94 | 342.12 | 118.92 | 4,959.13 | 0.00 |
Research and Development Expense of Revenue |
4,891.00% | 2,147.15% | 531.08% | 62,978.67% | 0.00% |
Selling, General and Administrative Expense of Revenue |
3,515.09% | 1,281.58% | 655.00% | 83,590.67% | 0.00% |
Intangible Assets out of Total Assets |
0.07 | 0.03 | 0.04 | 0.03 | 0.06 |
Share Based Compensation of Revenue |
0.00% | 64.96% | 22.08% | 3,268.00% | 0.00% |
Graham Net Nets |
0.42 | 0.42 | 0.05 | 2.20 | — |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | — |
Earnings Yield |
(187.72%) | (187.72%) | (155.77%) | (554.00%) | — |
Free Cash Flow Yield |
(204.09%) | (204.09%) | (104.59%) | (652.75%) | — |
Revenue per Share |
0.01 | 568.00 | 196.00 | 0.13 | 0.00 |
Operating CF per Share |
(0.67) | (16,699.00) | (2,103.54) | (178.35) | (23.03) |
Capex per Share |
0.00 | (673.60) | (90.94) | (6.64) | (0.38) |
Free Cash Flow per Share |
(0.67) | (17,372.60) | (2,194.49) | (184.99) | (23.40) |
Cash per Share |
0.67 | 6,985.40 | 513.14 | 79.77 | 4.24 |
Shareholders Equity per Share |
(2.13) | (72,520.60) | 832.31 | 99.80 | 7.80 |
Interest Debt per Share |
0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
Book value per Share |
(2.13) | (72,520.60) | 832.31 | 99.80 | 7.80 |
Free Cash Flow |
(8.07) | (8.69) | (7.68) | (10.56) | (11.41) |
Working Capital |
7.28 | 1.91 | 0.93 | 3.85 | 1.95 |
Capital Expenditures |
(0.65) | (0.34) | (0.32) | (0.38) | (0.18) |
Net Current Asset Value |
(27.48) | (39.29) | 0.33 | 3.57 | 1.80 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.27 | — |
Capex to Sales |
0.00 | 1.19 | 0.46 | 50.56 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | — |
| Other line items | |||||
Depreciation/Fixed assets |
0.09 | 0.49 | 1.09 | 1.36 | 0.83 |
Cash ROIC |
(47.55%) | 33.19% | (162.20%) | (102.92%) | (194.35%) |
Accounts Receivable Turnover |
0.00 | 0.95 | 2.80 | 0.05 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
0.00 | 0.00 | — | — | — |
Average Days of Payables |
3,089.59 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
0.00 | 0.00 | — | — | — |
Average Receivables |
— | 0.30 | 0.24 | 0.16 | 0.12 |
Average Payables |
— | 0.75 | 0.84 | 0.69 | 0.44 |
Average Assets |
— | 8.68 | 6.14 | 6.24 | 6.19 |
Average Common Equity |
— | (31.01) | (16.67) | 4.31 | 4.75 |
Columns are period end dates · fundamentals updated 2 Nov 2026